Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7461886 | 0.88 | FDPS (0.51) | ALDH1A1MAPK1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL9719099 | 0.88 | ALDH1A1 (0.68) | ALDH1A1MAPK1LMNAMAPTHTT | |
| SCHEMBL11765947 | 0.86 | ALDH1A1 (0.63) | ALDH1A1MAPK1LMNAMAPTHTT | |
| SCHEMBL31359168 | 0.86 | ALDH1A1 (0.66) | ALDH1A1MAPK1LMNAMAPTHTT | |
| SCHEMBL29254188 | 0.85 | TUBB1 (0.54) | ALDH1A1MAPK1LMNAL3MBTL1CYP1A2 | |
| SCHEMBL31004955 | 0.85 | TUBB1 (0.54) | ALDH1A1MAPK1LMNAL3MBTL1CYP1A2 | |
| SCHEMBL524712 | 0.84 | ALDH1A1 (0.63) | ALDH1A1MAPK1MAPTHTTKMT2A | |
| SCHEMBL30122857 | 0.84 | ALDH1A1 (0.63) | ALDH1A1MAPK1MAPTHTTKMT2A | |
| SCHEMBL6943688 | 0.84 | ALDH1A1 (0.64) | ALDH1A1MAPK1LMNAMAPTHTT | |
| SCHEMBL2649949 | 0.84 | ALDH1A1 (0.64) | ALDH1A1MAPK1LMNAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240335442-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | UNIVERSIDADE FEDERAL DO RIO DE JANEIRO – UFRJ (BR) | 2024-10-10 | — | — | US | disclosed |
| EP-4382100-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | Eurofarma Laboratórios S.A. (BR) | 2024-06-12 | — | — | EP | disclosed |
| CN-118076348-A | N-acylhydrazone compounds capable of inhibiting NAV 1.7 and/or NAV 1.8, methods of making, compositions, uses, methods of treatment and kits using the same | 欧罗法玛实验室股份公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2023010191-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | EUROFARMA LABORATÓRIOS S.A. (BR) | 2023-02-09 | — | — | WO | disclosed |
| WO-2023010191-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | EUROFARMA LABORATÓRIOS S.A. (BR) | 2023-02-09 | — | — | WO | disclosed |
| US-20180118679-A1 | N-Methyl Pyrazoles | Prosetta Antiviral ,Inc. | 2018-05-03 | — | — | US | disclosed |
| WO-2016161021-A1 | N-METHYL PYRAZOLES | Prosetta Antiviral, Inc. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20130131018-A1 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS | EXONHIT S.A. (FR) | 2013-05-23 | — | — | US | disclosed |
| US-20130131018-A1 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS | EXONHIT S.A. (FR) | 2013-05-23 | — | — | US | disclosed |
| US-20130131018-A1 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS | EXONHIT S.A. (FR) | 2013-05-23 | — | — | US | disclosed |
| EP-2576514-A1 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS | EXONHIT SA (FR) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011151423-A1 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS | EXONHIT S.A. (FR) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011151423-A1 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS | EXONHIT S.A. (FR) | 2011-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240335442-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | SCN1A, SCN7A, SCN8A | ALDH1A1 320/4885MAPK1 1978/4885LMNA 1066/4885 |
| US-20180118679-A1 | N-Methyl Pyrazoles | ZC3HAV1, MAVS, NNMT | ALDH1A1 3967/4885MAPK1 3077/4885LMNA 2802/4885 |
| US-20130131018-A1 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS | TUBB3, TUBB, TUBB1 | ALDH1A1 2257/4885MAPK1 2537/4885LMNA 1960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.